Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. Reply
- PMID: 37530836
- DOI: 10.1056/NEJMc2306786
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. Reply
Comment on
-
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical